Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Cue Biopharma Inc (CUE)

Cue Biopharma Inc (CUE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Cue Biopharma Announces $30 Million Private Placement GlobeNewswire - Thu Apr 30, 3:25PM CDT

BOSTON, April 30, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate...

CUE : 29.85 (-1.87%)
Cue Biopharma Expands Pipeline with Exclusive License from Ascendant Health Sciences Ltd. for Clinical-Stage Dual-Mechanism Anti-IgE Antibody GlobeNewswire - Thu Apr 30, 3:15PM CDT

Novel dual-mechanism anti-IgE antibody designed to improve upon existing and emerging therapies for IgE-mediated diseases Cue Biopharma plans to initiate global Phase 2b trial in food allergy following...

CUE : 29.85 (-1.87%)
Cue Biopharma Names Shao-Lee Lin M.D., Ph.D., CEO, President and Board Director to Lead Continued Growth and Transformation into a Clinical-Stage Company GlobeNewswire - Thu Apr 30, 3:05PM CDT

BOSTON, April 30, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.  (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and...

CUE : 29.85 (-1.87%)
Cue Biopharma Announces 1-for-30 Reverse Stock Split GlobeNewswire - Wed Apr 22, 7:37AM CDT

BOSTON, April 22, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.  (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and...

CUE : 29.85 (-1.87%)
Cue Biopharma to Present New Preclinical Data on Lead Autoimmune and Inflammatory Disease Candidate CUE-401 at IMMUNOLOGY2026 GlobeNewswire - Wed Apr 15, 7:00AM CDT

BOSTON, April 15, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.  (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and...

CUE : 29.85 (-1.87%)
Cue Biopharma to Receive $7.5 Million Preclinical Milestone Payment from Boehringer Ingelheim Collaboration and License Agreement GlobeNewswire - Wed Apr 8, 7:00AM CDT

Preclinical milestone for selection and approval of first compound for lead optimization has been achieved Further development validates the potential intended mechanistic effect of CUE-501 for T cell-mediated...

CUE : 29.85 (-1.87%)
Cue Biopharma Announces CEO Transition GlobeNewswire - Fri Mar 27, 3:05PM CDT

BOSTON, March 27, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.  (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and...

CUE : 29.85 (-1.87%)
Cue Biopharma to Host Virtual R&D Day Event on April 7, 2026 GlobeNewswire - Thu Mar 26, 7:00AM CDT

Virtual Event will feature Key Opinion Leaders (KOLs)  Richard DiPaolo, PhD, and Jonathan Kay, MD, FACP, MACR Cue Biopharma management and KOLs will discuss CUE-401, the company’s lead asset...

CUE : 29.85 (-1.87%)
Cue Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights GlobeNewswire - Mon Mar 16, 3:05PM CDT

Advanced research and development of CUE-401 for IND (Investigational New Drug) readiness – CUE-401 is the Company’s lead asset for the treatment of autoimmune and inflammatory diseases Appointed...

CUE : 29.85 (-1.87%)
Cue Biopharma to Present New In vitro Data for CUE-401 at the 20th World Immune Regulation Meeting (WIRM) 2026 GlobeNewswire - Mon Mar 9, 7:00AM CDT

BOSTON, March 09, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.  (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and...

CUE : 29.85 (-1.87%)

Barchart Exclusives

This Blue-Chip Dividend Stock Is Becoming an AI Star Barchart - Mon May 4, 6:30PM CDT
Caterpillar is increasingly being treated as an AI‑infrastructure play, with data‑center and hyperscale power demand now a visible, incremental growth driver layered on top of its core construction, mining, and energy cycles rather than a one‑off theme. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.